Vagus nerve stimulation (VNS) inhibits cardiac mast cells activation and improves myocardial atrophy after ischemic stroke

 But you incompetently did not tell us the protocol for that! How the fuck do you expect survivors to be able to tell their stroke medical 'professionals' what to do?

Do you suggest the surgery options or the easier ones?

I think most stroke survivors would rather do the non-invasive approaches. So ask your doctor why surgery; I'm guessing revenue and profits.

Dorset Embarks on Revolutionary Stroke Recovery Trial Utilizing Earpiece Technology February 2024

 

Non-invasive VNS approach could enhance post-stroke recovery outcomes August 2023

The latest here:

Vagus nerve stimulation (VNS) inhibits cardiac mast cells activation and improves myocardial atrophy after ischemic stroke

Author links open overlay panel, , , , , , , ,

,

https://doi.org/10.1016/j.intimp.2024.112714

Get rights and content

Under a Creative Commons license

open access

Highlights

• •

  Vagus nerve stimulation (VNS) can reduce myocardial atrophy after acute ischemic stroke;

• •

  VNS decreased the amount of Chyamse and inhibited mast cell activation in cardiac tissue after acute ischemic stroke;

• •

  VNS reduces the expression of angiotensin II (Ang II) after acute ischemic stroke by inhibiting mast cell activity, thereby alleviating cardiac inflammation and autophagy.

Abstract

Background

Ischemic stroke is one of the leading causes of chronic disability worldwide, and stroke-induced heart damage can lead to death. According to research, patients with a variety of brain disease have good clinical results after vagus nerve stimulation (VNS). After ischemic stroke, mast cells (MCs) degranulate and release a large number of mediators, which may cause systemic inflammation. Chymase secreted by MCs can increase the levels of pathological angiotensin II (AngⅡ), which plays a crucial role in the deterioration of heart disease. Our goal was to develop a minimally invasive, targeted, and convenient VNS approach to assess the impact of VNS and to clarify the relationship between VNS and MCs in the prognosis of patients with myocardial atrophy after acute ischemic stroke.

Methods

In this study, we verified the role of VNS in the treatment of myocardial atrophy after stroke and its molecular mechanism using a rat model of middle cerebral artery occlusion (MCAO/r). Behavioral studies were assessed using neurobehavioral deficit scores. Enzyme-linked immunosorbent assays, immunofluorescence staining, Western blotting and qRT-PCR were used to analyze the expression levels of myocardial atrophy, MC and inflammatory markers in rat hearts.

Results

VNS improved myocardial atrophy in MCAO/r rats, inhibited MC activation, reduced the expression of chymase and AngⅡ, and inhibited the expression of proinflammatory factors. The chymase activator C48/80 reversed these effects of VNS. Chymase activation inhibited the effect of VNS on myocardial atrophy in MCAO/r rats, increased AngⅡ expression and aggravated inflammation and autophagy. The myocardial atrophy of MCAO/r rats was improved after chymase inhibition, and AngⅡ expression, inflammation and autophagy were reduced. Our results suggest that VNS may reduce the expression of chymase and AngⅡ by inhibiting MC activation, thereby improving myocardial atrophy and reducing inflammation and autophagy in MCAO/r rats. Inhibition of MC activation may be an effective strategy for treating myocardial atrophy after stroke.

Conclusions

VNS inhibits MC activation and reduces the expression of chymase and AngII, thereby alleviating myocardial atrophy, inflammation and autophagy after stroke.